Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA Appoints Ms. Marie-Claire Janailhac-Fritsch as Chairwoman of the Board of Directors
Guerbet SA announced that it has appointed Ms. Marie-Claire Janailhac-Fritsch as the Company's Chairwoman of the Board of Directors. Ms. Janailhac-Fritsch will replace Mr. Jean-Jacques Bertrand, who resigned from his post.
Latest Developments for Guerbet SA
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
- Guerbet launches CE-marked FlowSens solution on global markets
- Guerbet SA receives FDA approval for new manufacturing plant for Lipiodol injection
Latest Key Developments in Pharmaceuticals
- IPCA Laboratories Ltd announces voluntary stoppage of shipments from Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Ratlam (Madhya Pradesh) for the US markets
- Gilead Sciences Inc raises FY 2014 net product sales guidance
- cross-border merger of Bioalliance Pharma SA and Topotarget is legally effective as of July 22, 2014
- U.S. Food and Drug Administration approves Gilead Sciences Inc' s Zydelig for relapsed chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma
- Share this
- Digg this